Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure.

GlobalUseof Peripheral BloodvsBoneMarrow as Sourceof StemCells forAllogeneic Transplantation inPatientsWithBoneMarrowFailure Hematopoietic stemcell transplantation (HSCT) is a therapeutic option formany patients with bonemarrow failure.1 Bone marrowwas initially the only stem cell source available until the 1990swhen peripheral blood stem cells (PBSCs) and cord blood began to be used. Currently, PBSCs are themajor stemcell source,2 owing to faster engraftment andease of collectiondespite a higher rate ofgraft-vs-hostdiseaseand lowersurvival rates inpatientswith nonmalignant disorders.3 Therefore, bone marrow is currently recommended for HSCT inpatientswithbonemarrow failure.4 Theobjectives of this studywere to investigate the use of PBSCs and bonemarrow as stem cell sources for HSCT in patients with bonemarrow failure worldwide and to identify potential factors associated with the use of each stem cell source.